SciELO - Scientific Electronic Library Online

 
vol.74 issue3Benign nasopharyngeal teratoma in an adult patientMaxillary mucocele in a 4-month infant author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Revista Brasileira de Otorrinolaringologia

Print version ISSN 0034-7299

Rev. Bras. Otorrinolaringol. vol.74 no.3 São Paulo May/June 2008

https://doi.org/10.1590/S0034-72992008000300029 

CASE REPORT

 

Ameloblastoma in the mandible

 

 

Marcelo MedeirosI; Gabriela Granja PortoII; Jose Rodrigues Laureano FilhoIII; Luís PortelaIV; Ricardo Holanda VasconcellosIII

ISpecialist in maxillo-facial surgery and traumatology, Master's program in maxillo-facial surgery and traumatology student
IISpecialist in maxillo-facial surgery and traumatology, MSc student - MFS FOP-UPE
IIIPhD in maxillo-facial surgery and traumatology, adjunct professor of maxillo-facial surgery and traumatology - University of Pernambuco
IVMSc in Biomedical Engineering, Assistant Professor of Tooth Implants at the University of Pernambuco

 

 


Keywords: ameloblastoma, surgery, mandible patology.


 

 

INTRODUCTION

The ameloblastoma is an enamel tissue tumor, which does not differentiate to form the enamel. It is benign and of ectodermic origin. Although considered a benign tumor, its clinical behavior can be considered of middle ground, between benign and malignant. The tumor is characterized by slow but persistent growth and infiltration in adjacent tissue1,2.

 

CASE PRESENTATION

R.T.B., male, 30 years old, came to the Department of Maxillo-Facial Surgery complaining of a bulging in his left-side mandible, which had been enlarging for the past ten years. An incisional biopsy was carried out through the oral cavity. The pathology finding was ameloblastoma. In order to better plan access to the lesion and mandible reconstruction after tumor exeresis, we made a model through the prototyping technique. Treatment chose was hemimandibulectomy, with mandibular condyle loosening on the ipsilateral side, since the tumor had already invaded the cortical bone, with immediate reconstruction with reconstruction plate and condyle coupled to it. Currently the patient has been under observation for four years, without signs of recurrence (Figure 1).

 

 

DISCUSSION

Ameloblastomas are classified in unicystic, solid or multicystic, peripheral and malignant subtypes in conventional or multicystic solid (86% of the cases), unicystic (13% of the cases) and peripheral or extra-osseous (about 1% of the cases)3. Such distinction is important because the treatment of a unicystic lesion can be more conservative, for it has a less aggressive behavior and smaller size than its solid or multicystic counterpart4.

Typical ameloblastoma starts insidiously as a central bony lesion which is slowly destructive; however tends to expand the bone instead of punching a hole through it. The tumor is rarely painful, unless infected and usually does not cause signs and symptoms of nerve involvement, even when large3.

Radiographically, the most common aspect of multicystic ameloblastomas is a multilocular lesion; often times described as having the appearance of "soap bubbles" when large, and are described as honeycomb when small. There is frequently a lingual cortical and oral expansion, and usually the teeth roots adjacent to the tumor are resorbed. Unicystic ameloblastomas present a radiolucent image that surrounds the crown of an unerupted tooth or, they simply appear as a well defined radiotransparent areas3.

Gender distribution as far as ameloblastomas are concerned is 1:14,5. The age of most frequent onset is the 3rd and 4th decades of life6. The mandible is about four times more affected than the maxilla6. About ¾ of mandible tumors are located in the mandible ramus and molar teeth. When it involves the maxilla, the posterior region is also the one most affected, and as it develops, the tumor may involve the maxillary sinus and the orbit5.

There is a trend to treat unicystic ameloblastomas by curettage with 10%-15% of recurrence; however, avoiding patient mutilation. In the solid or multicystic tumor, it is necessary to have radical surgical excision, with resection of the affected bone with at least 15 mm of healthy tissue as safety margin6. The mucosa in contact with the tumor must be entirely removed, because it may contain ameloblastic cells that can contaminate the graft during reconstruction1.

It is important to stress the capacity the tumor has to develop late recurrences. Because of its slow growth, these recurrences may take years, and even decades to happen after the first surgery1.

 

FINAL COMMENTS

Thus, we conclude that radical surgery is the treatment of choice most of the times. We must stress that radiographic methods are not able to determine the exact disease extension and the recurrence rate is close to 100% when not treated properly.

 

REFERENCES

1. Ferretti C, Polakow C, Coleman H. Recurrent Ameloblastoma: Report of 2 Cases. J Oral Maxillofac Surg 2000;58:800-4.         [ Links ]

2. AlKhateeb T, Ababneh KT. Ameloblastoma in Young Jordanians: A Review of the Clinicopathologic Features and Treatment of 10 Cases. J Oral Maxillofac Surg 2003;61:13-8.         [ Links ]

3. Neville BW, Damm DD, Allen CM, et al. Patologia Oral & Maxilofacial. Rio de Janeiro: Guanabara Koogan; 1998.         [ Links ]

4. Ord RA, Blanchaert Jr RH, Nikitakis NG, Sauk JJ. Ameloblastoma in Children. J Oral Maxillofac Surg 2002;60:762-70.         [ Links ]

5. Zwahlen RA, Vogt P, Fischer FS, Gra¨tz KW. Case Report: Myocardial Metastasis of a Maxillary Malignant Ameloblastoma. J Oral Maxillofac Surg 2003;61:731-4.         [ Links ]

6. Pizer ME, Page DG, Svirsky JA. ThirteenYear Follow-Up of Large Recurrent Unicystic Ameloblastoma of the Mandible in a 15 Year Old Boy. J Oral Maxillofac Surg 2002;60:211-5.         [ Links ]

 

 

This paper was submitted to the RBORL-SGP (Publishing Manager System) on 24 October 2006. code 3470.
The article was accepted on 5 November 2006.

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License